Melisa Cooper

739 total citations
20 papers, 583 citations indexed

About

Melisa Cooper is a scholar working on Pharmacology, Molecular Medicine and Epidemiology. According to data from OpenAlex, Melisa Cooper has authored 20 papers receiving a total of 583 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Pharmacology, 7 papers in Molecular Medicine and 5 papers in Epidemiology. Recurrent topics in Melisa Cooper's work include Antibiotics Pharmacokinetics and Efficacy (11 papers), Antibiotic Resistance in Bacteria (7 papers) and Pneumonia and Respiratory Infections (4 papers). Melisa Cooper is often cited by papers focused on Antibiotics Pharmacokinetics and Efficacy (11 papers), Antibiotic Resistance in Bacteria (7 papers) and Pneumonia and Respiratory Infections (4 papers). Melisa Cooper collaborates with scholars based in United Kingdom, United States and Australia. Melisa Cooper's co-authors include Robert A. Wise, J. M. Andrews, J. M. Andrews, M Logan, J. P. Ashby, R. Wise, Janet B. McGill, Tomás Berl, Raymond P. Bain and Edmund J. Lewis and has published in prestigious journals such as Kidney International, Journal of the American Society of Nephrology and Antimicrobial Agents and Chemotherapy.

In The Last Decade

Melisa Cooper

19 papers receiving 540 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Melisa Cooper United Kingdom 12 270 166 159 117 84 20 583
Raül Rigo‐Bonnin Spain 14 261 1.0× 149 0.9× 219 1.4× 37 0.3× 48 0.6× 78 741
Shuchean Chien United States 12 455 1.7× 305 1.8× 197 1.2× 28 0.2× 239 2.8× 14 896
Jiajun Liu United States 16 427 1.6× 233 1.4× 192 1.2× 193 1.6× 162 1.9× 41 1.0k
Nynke G L Jager Netherlands 15 266 1.0× 91 0.5× 57 0.4× 13 0.1× 45 0.5× 38 719
V. Malerczyk Germany 15 262 1.0× 71 0.4× 102 0.6× 23 0.2× 122 1.5× 46 575
Alex P. Betrosian Greece 16 197 0.7× 339 2.0× 256 1.6× 63 0.5× 14 0.2× 29 854
Hjalmar Lagast Belgium 17 242 0.9× 177 1.1× 153 1.0× 415 3.5× 286 3.4× 48 1.2k
Max Taubert Germany 13 207 0.8× 93 0.6× 71 0.4× 18 0.2× 17 0.2× 42 478
Christopher R. Curtin United States 13 232 0.9× 168 1.0× 86 0.5× 26 0.2× 284 3.4× 24 802
Hassan Gandjini France 10 374 1.4× 356 2.1× 506 3.2× 41 0.4× 125 1.5× 14 1.1k

Countries citing papers authored by Melisa Cooper

Since Specialization
Citations

This map shows the geographic impact of Melisa Cooper's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Melisa Cooper with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Melisa Cooper more than expected).

Fields of papers citing papers by Melisa Cooper

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Melisa Cooper. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Melisa Cooper. The network helps show where Melisa Cooper may publish in the future.

Co-authorship network of co-authors of Melisa Cooper

This figure shows the co-authorship network connecting the top 25 collaborators of Melisa Cooper. A scholar is included among the top collaborators of Melisa Cooper based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Melisa Cooper. Melisa Cooper is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Cooper, Melisa, David Z.I. Cherney, Tom Greene, et al.. (2024). Vascular Endothelial Growth Factor–B Blockade with CSL346 in Diabetic Kidney Disease. Journal of the American Society of Nephrology. 35(11). 1546–1557. 1 indexed citations
2.
Waller, Edmund K., Mitchell E. Horwitz, Sarah Anand, et al.. (2024). MODULAATE (Part 1): An Open-Label, Dose-Finding Phase 2 Evaluation of Alpha-1 Antitrypsin for the Prevention of Graft-Versus-Host Disease in Patients Receiving Hematopoietic Cell Transplantation. Transplantation and Cellular Therapy. 30(2). S261–S261. 2 indexed citations
3.
Cooper, Melisa, et al.. (2018). First‐in‐Human Studies for a Selective RET Tyrosine Kinase Inhibitor, GSK3179106, to Investigate the Safety, Tolerability, and Pharmacokinetics in Healthy Volunteers. Clinical Pharmacology in Drug Development. 8(2). 234–245. 2 indexed citations
4.
Nelsen, Linda, William R. Lenderking, Robin Pokrzywinski, et al.. (2017). Experience of Symptoms and Disease Impact in Patients with Adenomyosis. Patient. 11(3). 319–328. 28 indexed citations
5.
Amrine‐Madsen, Heather, et al.. (2017). Single‐ and Multiple‐Day Dosing Studies to Investigate High‐Dose Pharmacokinetics of Epelsiban and Its Metabolite, GSK2395448, in Healthy Female Volunteers. Clinical Pharmacology in Drug Development. 7(1). 33–43. 8 indexed citations
6.
Olsen, Nancy J., et al.. (2010). Phase 1, placebo-controlled, dose escalation trial of chicory root extract in patients with osteoarthritis of the hip or knee. BMC Musculoskeletal Disorders. 11(1). 156–156. 27 indexed citations
7.
Breyer, Julia A., Raymond P. Bain, N. Stanley Nahman, et al.. (1996). Predictors of the progression of renal insufficiency in patients with insulin-dependent diabetes and overt diabetic nephropathy. Kidney International. 50(5). 1651–1658. 180 indexed citations
8.
Cooper, Melisa, J. M. Andrews, & R. Wise. (1992). In-vitro activity of PD 131628, a new quinolone antimicrobial agent. Journal of Antimicrobial Chemotherapy. 29(5). 519–527. 10 indexed citations
9.
Cooper, Melisa, J. M. Andrews, & R. Wise. (1992). In-vitro activity of tosufloxacin, a new quinolone antibacterial agent. Journal of Antimicrobial Chemotherapy. 29(6). 639–647. 3 indexed citations
10.
Johnson, James H., Melisa Cooper, J. M. Andrews, & Robert A. Wise. (1992). Pharmacokinetics and inflammatory fluid penetration of sparfloxacin. Antimicrobial Agents and Chemotherapy. 36(11). 2444–2446. 57 indexed citations
11.
Cooper, Melisa, J. M. Andrews, & Robert A. Wise. (1992). Absence of bactericidal activity of sparfloxacin and ciprofloxacin under anaerobic conditions. Journal of Antimicrobial Chemotherapy. 29(5). 589–590. 1 indexed citations
12.
Cooper, Melisa, David Baldwin, Richard Matthews, J. M. Andrews, & R. Wise. (1991). In-vitro susceptibility of Chlamydia pneumoniae (TWAR) to seven antibiotics. Journal of Antimicrobial Chemotherapy. 28(3). 407–413. 12 indexed citations
13.
Cooper, Melisa, J. M. Andrews, & R. Wise. (1991). Bactericidal activity of sparfloxacin and ciprofloxacin under anaerobic conditions. Journal of Antimicrobial Chemotherapy. 28(3). 399–405. 17 indexed citations
14.
Cooper, Melisa, et al.. (1991). In-vitro activity and β-lactamase stability of SR 44337, a new long acting cephalosporin. Journal of Antimicrobial Chemotherapy. 28(2). 229–237. 1 indexed citations
15.
Wise, Robert A., M Logan, Melisa Cooper, & J. M. Andrews. (1991). Pharmacokinetics and tissue penetration of tazobactam administered alone and with piperacillin. Antimicrobial Agents and Chemotherapy. 35(6). 1081–1084. 61 indexed citations
16.
Cooper, Melisa, J. M. Andrews, J. P. Ashby, Richard Matthews, & R. Wise. (1990). In-vitro activity of sparfloxacin, a new quinolone antimicrobial agent. Journal of Antimicrobial Chemotherapy. 26(5). 667–676. 53 indexed citations
17.
Cooper, Melisa, Ye Jin, J. P. Ashby, J. M. Andrews, & Robert I. Wise. (1990). In-vitro comparison of the postantibiotic effect of vancomycin and teicoplanin. Journal of Antimicrobial Chemotherapy. 26(2). 203–207. 16 indexed citations
18.
Cooper, Melisa, K. Nye, J. M. Andrews, & Robert A. Wise. (1990). The pharmacokinetics and inflammatory fluid penetration of orally administered azithromycin. Journal of Antimicrobial Chemotherapy. 26(4). 533–538. 42 indexed citations
19.
Wise, Robert A., M Logan, Melisa Cooper, J. P. Ashby, & J. M. Andrews. (1990). Meropenem pharmacokinetics and penetration into an inflammatory exudate. Antimicrobial Agents and Chemotherapy. 34(8). 1515–1517. 47 indexed citations
20.
Riley, Louis J., Melisa Cooper, & Robert G. Narins. (1989). Alkali therapy of diabetic ketoacidosis: Biochemical, physiologic, and clinical perspectives. Diabetes/Metabolism Reviews. 5(8). 627–636. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Raül Rigo‐Bonnin Breakdown of academic impact, for papers by Shuchean Chien Breakdown of academic impact, for papers by Jiajun Liu Breakdown of academic impact, for papers by Nynke G L Jager Breakdown of academic impact, for papers by V. Malerczyk Breakdown of academic impact, for papers by Alex P. Betrosian Breakdown of academic impact, for papers by Hjalmar Lagast Breakdown of academic impact, for papers by Max Taubert Breakdown of academic impact, for papers by Christopher R. Curtin Breakdown of academic impact, for papers by Hassan Gandjini
Rankless by CCL
2026